Shots:

• The clinical study data results support the therapeutic benefits of Gen-2, 15 Milliamp Neurostimulation Device at the Vertigo Center, Department of Neurology, Second Affiliated Hospital of Zhengzhou University. The trial was funded by the company’s joint venture partner, Wider & its related companies while treatment was given over 4wks. with a 4wk. follow-up period
• The results showed a significant benefit & suggested a reduction in frequency & degree of pain in migraine patients along with a strong safety profile, presented in Chin J Neuromed
• Improvement across all key metrics, incl. VAS, PSQI, HAMA, HAMD & MSQ scores which evaluating the severity & impact of migraine and related symptoms, as well as the effectiveness of treatment with no AEs

Ref: Globenewswire | Image: Nexalin

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com